Sun Pharma in distribution agreement with AstraZeneca for brand Axcer

Sun Pharma will be promoting and distributing Axcer brand in India

AstraZeneca Pharma India Limited (AZPIL) and Sun Pharma have entered into a distribution services agreement in India for AstraZeneca’s brand ‘Axcer’, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark ‘Brilinta’, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012.

Abhay Gandhi, Chief Executive Officer – India Business, Sun Pharma said, “Such collaborations are also a part of our stated policy of becoming the partner of choice for promotion and distribution of innovative pharmaceutical products in the country.”

Sanjay Murdeshwar, Managing Director, AZPIL said, “Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient’s risk of another heart attack or cardiovascular-related death.”

Sun Pharma will be promoting and distributing Axcer brand in India. This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients. It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy.

Abhay Gandhiacute coronary syndromeAstraZeneca Pharma India LimitedAxcerSanjay MurdeshwarSun Pharmaceutical Industries